Global Information
회사소개 | 문의 | 비교리스트

암 지지요법 : 종합 개요, 파이프라인 제품, R&D 전략, 충족되지 않은 욕구

Supportive Care in Cancer - Comprehensive Overview, Pipeline Products, Research and Development Strategies and Unmet Needs

리서치사 GlobalData
발행일 2020년 12월 상품 코드 982513
페이지 정보 영문 146 Pages
가격
US $ 7,995 ₩ 9,718,000 PDF (Single User License) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 15,990 ₩ 19,437,000 PDF (Site License) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 23,985 ₩ 29,156,000 PDF (Global License) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


암 지지요법 : 종합 개요, 파이프라인 제품, R&D 전략, 충족되지 않은 욕구 Supportive Care in Cancer - Comprehensive Overview, Pipeline Products, Research and Development Strategies and Unmet Needs
발행일 : 2020년 12월 페이지 정보 : 영문 146 Pages

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

일부 암 지지요법(SCC) 적응증의 치료 발전과 함께 질환의 메커니즘 이해 향상이 이 분야의 인식을 높일 것으로 예측되고 있습니다.

일부 SCC 적응증에서 상당한 치료 발전이 이루어졌지만, 분야 전체 분석에서는 특히 승인된 치료법이 존재하지 않는 적응증의 현재 치료 옵션에 관해 격차가 있음을 나타내고 있습니다.

임상 개발 파이프라인의 폭넓은 제품은 특히 승인된 치료법 측면에서 현재 서비스가 부족한 적응증에 대한 SCC에 있어서 유망합니다.

SCC 분야의 임상적/환경적 충족되지 않은 욕구는 의약품 기업과 정책 입안자가 각각 효과적인 치료법과 프레임워크 개발을 지원하고, 분야를 한층 더 발전시킬 기회를 제공합니다. 특히 일부 SCC 적응증에 대해 삶의 질 향상과 규제기관의 프레임워크 개선 등의 측면에서 환자에게 상당한 이점을 제공할 수 있는 치료법은 기존의 격차를 해결하는 데 있어서 특히 중요합니다.

암 지지요법(SCC: Supportive Care in Cancer)에 대해 조사했으며, SCC 적응증의 역학 개요, 적응증에 사용되는 치료 가이드라인과 현재의 치료 옵션 개요, SCC 현황과 향후 상황에 관한 KOL(Key Opinion Leader)의 견해 등에 대해 전해드립니다.

목차

목차

제1장 서문

  • 목차
  • 약어
  • 관련 보고서

제2장 개요

  • 주요 조사 결과

제3장 암 지지요법 개요

  • 암 지지요법이란?

제4장 역학

  • 암 발생자수
  • 화학요법을 받고 있는 전체 발생자수
  • 증상이 있고 화학요법을 받고 있는 전체 발생자수
  • 암전체 5개년 환자 수

제5장 현재 및 향후 치료 가이드라인 상황

  • 암 지지요법 적응증별 치료 가이드라인 : 조사 결과
  • 치료 가이드라인을 준수하지 않는 이유 : KOL(Key Opinion Leader)의 견해
  • 암 지지요법 적응증을 위해 일반적으로 사용되는 치료 가이드라인
  • 암 지지요법 현황 : KOL(Key Opinion Leader)의 견해
  • 암 지지요법에 대한 의사 태도 : KOL(Key Opinion Leader)의 견해
  • 암 지지요법 전망 : KOL(Key Opinion Leader)의 견해
  • 암면역치료와 표적치료가 SCC에 미치는 영향 : KOL(Key Opinion Leader)의 견해
  • 새로운 부작용 프로파일 작성에서 암면역치료와 표적치료의 역할 : KOL(Key Opinion Leader)의 견해

제6장 현재의 치료 옵션

  • 암 지지요법 적응증별 주요 MOA
  • 암 지지요법 적응증별 주요 시판 제품 정보
  • 암 지지요법 적응증별 일반적으로 사용되고 있는 시판 제품 : 조사 결과
  • 암 지지요법 적응증별 시판 제품 만족도 : 조사
  • 결과
  • 암 지지요법 적응증별 시판 제품 : KOL의 전망

제7장 파이프라인 제품과 R&D 전략

  • 암 지지요법 적응증별 연구개발 전략에 관한 지식과 가능성 레벨 - 조사 결과
  • 암 지지요법 적응증별 파이프라인 제품 : KOL(Key Opinion Leader)의 견해

제8장 임상시험 설계와 과제

  • 암 지지요법 적응증별 임상시험 과제와 엔드포인트 : 조사 결과
  • 암 지지요법 적응증별 임상시험 과제와 엔드포인트 : KOL(Key Opinion Leader)의 견해

제9장 충족되지 않은 욕구와 기회

  • 암 지지요법 적응증별 주요 충족되지 않은 욕구
  • 암 지지요법 적응증별 충족되지 않은 욕구의 중요성 수준 : 조사 결과
  • 암 지지요법 적응증별 충족되지 않은 욕구 : KOL(Key Opinion Leader)의 견해

제10장 부록

LSH 21.02.01

Supportive care in cancer is an evolving discipline of medicine that is critical for holistic management of patients with cancer. With significant advancements being made in treatment of cancer particularly through development of immuno-oncology (IO) and targeted therapies, it is of equal significance to focus on supportive care in cancer so as to ensure that patients are able to complete the treatment cycle for the primary cancer as well as to enhance their quality of life.

The report leverages on survey-based data and KOL insights to provide a comprehensive overview on a number of aspects including current treatment options that are used for various indications within SCC and treatment guidelines that are observed for these indications. In terms of clinical development, pipeline products and R&D strategies for individual indications are addressed. The report also delves into some of the clinical trials challenges that are encountered in this field and provides an overview of unmet needs that exist for various SCC indications.

Key Highlights

  • Advancements in understanding of disease mechanisms coupled along with therapeutic advancements in some of the SCC indications are expected to increase awareness of this field.
  • Although significant therapeutic advancements have been made for some SCC indications, analysis of the overall field indicate that there is disparity in terms of current treatment options, particularly for indications in which approved therapies are non-existent.
  • Breadth of pipeline products in clinical development holds promise for SCC particularly for indications that are currently under-served in terms of approved therapies.
  • Existence of both clinical and environmental unmet needs within SCC field provide an opportunity for pharmaceutical companies and policy makers to help develop effective therapeutics and frameworks respectively, to advance the field further. Therapies that can offer a significant benefit to patients particularly in terms of improving quality of life and frameworks from regulatory agencies that can facilitate guidance, specifically on some SCC indications are of particular importance to help address the existing gap.

Key Questions Answered

  • What set of treatment guidelines and treatment options are used by oncologists in the 7MM for various indications within SCC?
  • What is the current status of SCC particularly with regards to physician attitude and how is this trend likely to change in the future? What sort of impacts are newer agents such as those related to IO and targeted therapies having on the SCC field?
  • What are the different R&D strategies that are being pursued by pharmaceutical companies within individual indications under SCC? What are the challenges associated with clinical trials in this field?
  • What are the current unmet needs, and what steps are being taken to help address these gaps in SCC?

Scope

  • Overview of epidemiology of various indications within SCC.
  • Overview of treatment guidelines and on current treatment options used for various indications within SCC as well as KOL perspectives on current and future status of SCC.
  • R&D strategies pursued by companies through pipeline products in development for various indications within SCC and KOL opinions of these mechanisms of action.
  • Clinical trials challenges and design factors to be considered for various indications within SCC.
  • Review of current unmet needs in the SCC market and overview of strategies adopted by companies within this space to help address the gaps in the market.

Reasons to Buy

The report will enable you to -

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the global SCC market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the SCC market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents

Table of Contents

1. Preface

  • 1.1. Table of Contents
  • 1.2. Abbreviations
  • 1.3. Related Reports

2. Executive Summary

  • 2.1. Key Findings

3. Supportive Care in Cancer Overview

  • 3.1. What is Supportive Care in Cancer?

4. Epidemiology

  • 4.1. Diagnosed Incident Cases of All Cancer in 2019
  • 4.2. Diagnosed Incident Cases of All Cancer Receiving Chemotherapy
  • 4.3. Diagnosed Incident Cases of All Cancer Receiving Chemotherapy with Condition
  • 4.4. Five-Year Diagnosed Prevalent Cases of All Cancer

5. Current and Future Status of Treatment Guidelines

  • 5.1. Treatment Guidelines for Various Indications Within Supportive Care in Cancer - Survey Results
  • 5.2. Reasons for Non-Adherence to Treatment Guidelines - KOL Opinion
  • 5.3. Commonly Used Treatment Guidelines for Indications Within Supportive Care in Cancer
  • 5.4. Current Status of Supportive Care in Cancer - KOL Opinion
  • 5.5. Physician Attitude Towards Supportive Care in Cancer - KOL Opinion
  • 5.6. Future Outlook for Supportive Care in Cancer - KOL Opinion
  • 5.7. Impact of Immuno-Oncology Therapies and Targeted Therapies on SCC - KOL Opinion
  • 5.8. Role of Immuno-Oncology Therapies and Targeted Therapies on Producing New Side Effect Profiles - KOL Opinion

6. Current Treatment Options

  • 6.1. Key MOAs for Various Indications Within Supportive Care in Cancer
  • 6.2. Key Marketed Product Information for Various Indications Within Supportive Care in Cancer
  • 6.3. Commonly Used Marketed Products for Various Indications Within Supportive Care in Cancer - Survey Results
  • 6.4. Level of Satisfaction With Marketed Products for Various Indications Within Supportive Care in Cancer - Survey
  • Results
  • 6.5. Marketed Products for Various Indications Within Supportive Care in Cancer - KOL Perspective

7. Pipeline Products and R&D Strategies

  • 7.1. Level of Familiarity and Potential for R&D Strategies for Various Indications Within Supportive Care in Cancer -
  • Survey Results
  • 7.2. Pipeline Products for Various Indications Within Supportive Care in Cancer - KOL Opinion

8. Clinical Trial Design and Challenges

  • 8.1. Clinical Trials Challenges and Endpoints for Various Indications Within Supportive Care in Cancer - Survey Results
  • 8.2. Clinical Trials Challenges and Endpoints for Various Indications Within Supportive Care in Cancer - KOL Opinion

9. Unmet Needs and Opportunities

  • 9.1. Major Unmet Needs for Various Indications Within Supportive Care in Cancer
  • 9.2. Level of Significance of Unmet Needs for Various Indications Within Supportive Care in Cancer - Survey Results
  • 9.3. Unmet Needs for Various Indications Within Supportive Care in Cancer - KOL Opinion

10. Appendix

  • 10.1. Primary Research: High-Prescriber Survey Respondent Demographics
  • 10.2. Primary Research: KOL Information
  • 10.3. About the Authors
  • 10.4. About GlobalData
  • 10.5. Contact Us
  • 10.6. Disclaimer
Back to Top
전화 문의
F A Q